An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1

doi:10.1016/j.yexcr.2023.113490

科研成果详情

题名	An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1
作者	Hu, Xuanxuan 1; Li, Meiqi1; Zhang, Yu 1; Sang, Kanru 2; Zhang, Yejun1; Li, Wulan3; Liu, Bo 3; Wan, Leyu 4; Du, Bang 2; Qian, Jinheng5; Meng, Fanxi 5; Fu, Yanneng5; Dai, Meijuan 6; Gao, Guohui7,8; Ye, Hui1
发表日期	2023-03-01
发表期刊	Experimental cell research 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Angiogenesis Osteoclast differentiation Phage display technology Rheumatoid arthritis THY-1 Ab
其他关键词	PHAGE DISPLAY ; MACROPHAGES ; ACTIVATION ; EXPRESSION ; BIOLOGICS ; THY-1 ; TLR4 ; JUNB
摘要	Thymocyte antigen-1 (THY-1)is a potential target for rheumatoid arthritis (RA) treatment, and THY-1 positive fibroblast-like synoviocytes (FLS) are enriched in the synovium of RA patients and participate in angiogenesis to accelerate RA progression. In this study, we screened an antibody targeting THY-1 (THY-1 Ab) and explored its mechanism in alleviating RA progression. THY-1 Ab was screened from ScFv phage antibody library by phage display technology (PDT). THY-1 Ab-treated collagen induced arthritis (CIA) mice had lower degree of arthritis scores. We explore the mechanism of THY-1 Ab in alleviating RA progression. THY-1 Ab can remarkably inhibit the secretion of pro-inflammatory factors and promote the secretion of anti-inflammatory factors. Further experiments showed that THY1 Ab downregulated the expression of JUNB by the hsa_circ_0094342/miRNA-155-5P/SPI1 axis, inhibited RA angiogenesis and osteoclast differentiation, and relieved RA progression. These findings support that THY-1 Ab is a promising therapeutic antibody for RA treatment.
资助项目	National Natural Science Foundation of China [82071836]; Natural Science Foundation of Zhejiang Province, PRC [LY17H060008]; Zhejiang Provincial Foundation for Health Department [2015KYA150]; Wenzhou Municipal basic scientific research project [Y2020240]; National Innovation & Entrepreneurship Training Program for College Students [202110343022]
出版者	ELSEVIER INC
ISSN	0014-4827
EISSN	1090-2422
卷号	424 期号:1
DOI	10.1016/j.yexcr.2023.113490
页数	14
WOS类目	Oncology ; Cell Biology
WOS研究方向	Oncology ; Cell Biology
WOS记录号	WOS:000933642100001
收录类别	PUBMED ; SCIE ; SCOPUS
在线发表日期	2023-02
URL	查看原文
PubMed ID	36706943
SCOPUSEID	2-s2.0-85147201283
通讯作者地址	[Ye, Hui]School of Basic Medical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China ; [Gao, Guohui]School of Laboratory Medicine and Life Sciences,WenZhou Medical University,Zhejiang,Wenzhou,325035,China
Scopus学科分类	Cell Biology
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/172529
专题	基础医学院（机能实验教学中心）温州医科大学检验医学院（生命科学学院、生物学实验教学中心）药学院（分析测试中心）第一临床医学院（信息与工程学院）、附属第一医院附属第一医院
通讯作者	Gao, Guohui; Ye, Hui
作者单位	1.School of Basic Medical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 2.The First School of Clinical Medicine,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 3.The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 4.School of Stomatology,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 5.School of Pharmaceutical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 6.The Second School of Clinical Medicine,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 7.School of Laboratory Medicine and Life Sciences,WenZhou Medical University,Zhejiang,Wenzhou,325035,China; 8.Key Laboratory of Laboratory Medicine,Ministry Education,Zhejiang,Wenzhou,325035,China
第一作者单位	基础医学院（机能实验教学中心）
通讯作者单位	基础医学院（机能实验教学中心）; 检验医学院（生命科学学院、生物学实验教学中心）
第一作者的第一单位	基础医学院（机能实验教学中心）
推荐引用方式 GB/T 7714	Hu, Xuanxuan,Li, Meiqi,Zhang, Yu,et al. An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1[J]. Experimental cell research,2023,424(1).
APA	Hu, Xuanxuan., Li, Meiqi., Zhang, Yu., Sang, Kanru., Zhang, Yejun., ... & Ye, Hui. (2023). An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1. Experimental cell research, 424(1).
MLA	Hu, Xuanxuan,et al."An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1".Experimental cell research 424.1(2023).